

1 **Patient-Specific Connectomic Models Correlate With, But Do Not Predict, Outcomes in Deep**
2 **Brain Stimulation for Obsessive-Compulsive Disorder**

3 Alik S. Widge^{1,+}, Fan Zhang², Aishwarya Gosai³, George Papadimitrou³, Peter Wilson-Braun³,
4 Magdalini Tsintou³, Senthil Palanivelu³, Angela M. Noecker⁴, Cameron C. McIntyre⁴, Lauren
5 O'Donnell², Nicole C.R. McLaughlin⁵, Benjamin D. Greenberg^{5,6}, Nikolaos Makris³, Darin D.
6 Dougherty^{3,*}, Yogesh Rathi^{2,3,*}

7

8 1: Department of Psychiatry, University of Minnesota, Minneapolis, MN

9 2: Department of Radiology, Brigham and Womens Hospital, Boston, MA

10 3: Department of Psychiatry, Massachusetts General Hospital, Boston, MA

11 4: Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH

12 5: Department of Psychiatry and Human Behavior, Butler Hospital and Brown University Medical
13 School, Providence, RI

14 6: Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, Providence, RI

15 *: Equal contribution as senior authors

16 +: Correspondence to: MTRF 3-208, 2001 6th St SE, Minneapolis, MN 55455 ; awidge@umn.edu

17 Running Title: Patient-Specific Models in DBS for OCD

18 Keywords: Diffusion magnetic resonance imaging (dMRI); neurostimulation ; machine learning ; internal
19 capsule ; electric field modeling

20

21 **Abstract**

22 Background: Deep brain stimulation (DBS) of the ventral internal capsule/ventral striatum (VCVS) is an
23 emerging treatment for obsessive-compulsive disorder (OCD). Recently, multiple studies using
24 normative connectomes have correlated DBS outcomes to stimulation of specific white matter tracts.
25 Those studies did not test whether these correlations are clinically predictive, and did not apply cross-
26 validation approaches that are necessary for biomarker development. Further, they did not account for
27 the possibility of systematic differences between DBS patients and the non-diagnosed controls used in
28 normative connectomes.

29

30 Methods: We performed patient-specific diffusion imaging in 8 patients who underwent VCVS DBS for
31 OCD. We delineated tracts connecting thalamus and subthalamic nucleus (STN) to prefrontal cortex via
32 VCVS. We then calculated which tracts were likely activated by individual patients' DBS settings. We fit
33 multiple statistical models to predict both OCD and depression outcomes from tract activation. We
34 further attempted to predict hypomania, a VCVS DBS complication. We assessed all models'
35 performance on held-out test sets.

36

37 Results: No model predicted OCD response, depression response, or hypomania above chance.
38 Coefficient inspection partly supported prior reports, in that capture of tracts projecting to cingulate
39 cortex was associated with both YBOCS and MADRS response. In contrast to prior reports, however,
40 tracts connected to STN were not reliably correlated with response.

41

42 Conclusions: Patient-specific imaging and a guideline-adherent analysis were unable to identify a
43 tractographic target with sufficient effect size to drive clinical decision-making or predict individual
44 outcomes. These findings suggest caution in interpreting the results of normative connectome studies.

45

46

47 **Introduction**

48 Deep brain stimulation (DBS) is an emerging approach to treatment-resistant mental disorders (1–3),
49 but response rates in formal clinical trials are mixed (1,4–7). More reliable outcomes might be achieved
50 by improving anatomic targeting. As psychiatric disorders are increasingly understood as network
51 disorders (8,9), psychiatric DBS is moving away from using a single nucleus/structure as the target and
52 towards attempts at affecting networks (1,10–12). There is particular enthusiasm for identifying target
53 networks through diffusion tractography, which may enable DBS electrode placement to be customized
54 to individual patients' anatomy. Although there is controversy over how accurately tractography
55 reconstructs white matter anatomy (13,14), remarkable early results have been reported from DBS
56 placement based on that imaging (10). Further, there are multiple tools available to model the
57 interaction of DBS electric fields and targeted tracts (15–17). These tools could replace trial-and-error
58 DBS programming with a mathematically optimal approach to activating desired pathways while
59 minimizing off-target effects (18). That could overcome the difficulty of correctly programming
60 stimulation, a likely driver of inconsistent clinical outcomes (1,4,19).

61

62 To realize that promise, we need to know which tracts should/should not be stimulated. For DBS of the
63 subcallosal white matter for depression, multiple groups have settled on a specific white matter
64 confluence and are studying it prospectively (with varying clinical outcomes (10,20)). For obsessive-
65 compulsive disorder (OCD), a consensus may also be emerging. A theory linking OCD to dysfunction in
66 cortico-striato-thalamic connectivity (21,22) has led to a focus on white matter tracts linking prefrontal
67 cortex (PFC) to striatum, basal ganglia, and thalamus. Retrospective studies from multiple institutions
68 have implicated tracts to/from dorsolateral PFC (23,24), ventrolateral PFC (12,25,26), and anterior
69 cingulate (12,24) as potentially important in response. Recent analyses of patients implanted at two
70 different targets correlated OCD response with a tract linking the ventral internal capsule/striatum
71 (VCVS) and the subthalamic nucleus (STN) with the medial PFC (12,26–28). One study further
72 suggested that capture of tracts from orbitofrontal cortex (OFC) (23) led to non-response, although a

73 qualitative synthesis (29) suggests that effective DBS tends to activate OFC-related fibers, and OFC-
74 directed circuits can drive compulsive behaviors in animal models (30–32).

75

76 Although promising, these prior tractographic analyses are also limited. Many used standard atlases or
77 connectomes derived from healthy controls, comparing these maps against electric fields from patient-
78 specific DBS placements (12,23,27,28). Individual patients, however, show dramatic variation in their
79 white matter topography compared to atlas standards (33). Targeting maps computed using
80 “normative” connectomes differ from those computed from patient-specific DTI images (24). Other
81 studies used simple isotropic field models (25), or distance between electrodes and a target tract (34)
82 which may not accurately capture the DBS-induced electric field (16,35).

83

84 Most importantly, these analyses focused on tracts that correlate with clinical response. A variable may
85 correlate strongly with an outcome but not be able to reliably predict that outcome, e.g. if the means are
86 separate but the tails of two distributions overlap (36–38). Best practices in biomarker research suggest
87 explicitly building predictive models, testing those models on held-out data, and reporting predictive
88 performance in addition to correlation (36,37,39,40). Prediction-oriented analyses might better answer
89 the question of whether a tractographic finding can be used as a programming target, i.e. whether it has
90 strong predictive accuracy at the single-patient level (41).

91

92 Here, we address these limitations through an explicit attempt to predict single-patient response to DBS
93 for OCD at the VCVS target, based on more precise field modeling approaches and using patient-
94 specific tractography. We replicate in part prior studies’ findings that cingulate, medial PFC, and lateral
95 PFC tracts are correlated with clinical response, but we show that these correlations do not provide
96 strong clinical predictive power, and in some cases we identify correlations that contradict earlier
97 reports.

98 **Methods**

99 *Study Population and Clinical Treatment*

100 Participants were 6 patients who enrolled in a clinical trial (NCT00640133) of VCVS DBS for OCD (42),
101 plus 2 who received VCVS DBS for OCD under a Humanitarian Device Exemption. All patients
102 received Medtronic model 3387 DBS leads, with the most ventral contact targeted to the ventral striatal
103 grey matter. The Institutional Review Boards of Massachusetts General Hospital and Butler Hospital
104 approved the protocols and provided ethical oversight. All participants gave informed consent, explicitly
105 including separate consent for DBS and for neuroimaging. We report here all patients who agreed to
106 undergo imaging. We analyzed both the Yale-Brown Obsessive-Compulsive Scale (YBOCS) and
107 Montgomery-Asberg Depression Rating Scale (MADRS), collected at visits approximately 2-4 weeks
108 apart by a trained rater.

109 *Imaging and Patient-Specific Tractography*

110 Pre-operative MRI data were acquired on a 3T Siemens TimTrio scanner. Diffusion MRI (dMRI) scans
111 had a spatial resolution of 2 mm (isotropic) with 10 non-diffusion weighted volumes and 60 diffusion
112 weighted volumes, with gradient directions spread uniformly on the sphere with a b-value of 700 s/mm².
113 dMRI data were registered to pre-operative T1- and T2-weighted MRI images and post-operative CT
114 scans using a published pipeline (43) available at <https://github.com/pnlbwh/>. We then performed whole
115 brain tractography from the dMRI data, using a multi-tensor unscented Kalman filter (UKF) (44,45). The
116 UKF fits a mixture model of two tensors to the dMRI data, providing a highly sensitive fiber tracking
117 ability in the presence of crossing fibers (46–49). The UKF method guides each fiber's current tracking
118 estimate by the previous one. This recursive estimation helps stabilize model fitting, making tracking
119 more robust to imaging artifact/noise. Another benefit of UKF is that fiber tracking orientation is
120 controlled by a probabilistic prior about the rate of change of fiber orientation, producing more accurate
121 tracking than the hard limits on curvature used in typical tractography algorithms. We combined the
122 UKF with a fiber clustering algorithm to create an anatomically curated and annotated white matter

123 atlas (48). The clustering method groups the streamlines from each patient using a spectral embedding
124 algorithm. Each fiber cluster is matched to a tract from an *a priori* labelled atlas of the white matter
125 derived from known connections in monkey and human brains. Fiber clustering was performed only on
126 streamlines longer than 40 mm to annotate medium and long range tracts.

127

128 *Tract Activation Modeling*

129 For each clinical DBS setting used in each patient, we calculated the volume of tissue activated (VTA)
130 using a modified version of StimVision (15). Briefly, the VTAs were calculated using artificial neural
131 network predictor functions, which were based on the response of multi-compartment cable models of
132 axons coupled to finite element models of the DBS electric field (50). The VTAs used in this study were
133 designed to estimate the spatial extent of activation for large diameter (5.7 μm) myelinated axons near
134 the DBS electrode (51).

135

136 Based on theories that VCVS DBS acts by modulating circuits that run primarily in the internal capsule
137 (14,22,29), we estimated activation of pathways linking thalamus with anterior cingulate and
138 pericingulate cortex (ACC-PAC), dorsolateral PFC (dlPFC), ventrolateral PFC (vlPFC), dorsomedial
139 PFC (DMPFC), medial orbitofrontal cortex (MOFC) and lateral OFC (LOFC). Pericingulate cortex
140 includes rostral pre-cingulate cortex, but not the dorsal prefrontal cortex (such as the supplementary
141 motor area). The atlas-guided fiber clustering algorithm (48) and a fiber clustering pipeline (52,53)
142 guided manual delineation of fiber bundles connecting these regions to thalamus. All pathway labelings
143 were performed by an expert neuroanatomist (Dr. Makris). Examples of the traced bundles and their
144 intersections with DBS VTAs are shown in Figure 1A. Recent reports found that a tract connecting
145 subthalamic nucleus (STN) to medial prefrontal cortex was strongly associated with clinical response to
146 DBS in OCD (12,26–28). Therefore, we manually segmented the STN in each subject and extracted all
147 fiber tracts connecting the STN with the prefrontal cortex (Figure 1B).

148

149 [Figure 1 about here]

150

151 *Data Analysis - Independent/Predictor Variables*

152 It is unclear whether the important “dose” of DBS is activation of a sufficient number of fibers (“total
153 fiber” model), vs. the degree to which a sub-circuit is influenced (i.e., the fraction of the overall
154 streamlines in a tract that are within the VTA, or a “percentage” model). We calculated both and fit them
155 as two separate models for each dependent clinical outcome (see below). We also considered the
156 possibility that DBS response is not determined by any individual tract/pathway, but instead requires
157 capture of multiple pathways simultaneously. We therefore added a “total activation” variable to each
158 prediction model. For total fiber models, this variable represented the total number of streamlines
159 activated for all tracts. For percentage models, it represented the mean percentage activation across all
160 reconstructed tracts. We standardized all input variables to the 0-1 interval to ensure that regression
161 coefficients were comparable between independent variables.

162

163 All models were fit and evaluated using scikit-learn (0.24.1) in Python (3.8.5). With the exception of a
164 necessary condition analysis described below, variables were coded at the single-visit level. That is, we
165 predicted the clinical outcome at visit T from the DBS settings programmed at visit T-1.

166

167 *Data Analysis - OCD Response*

168 White matter pathway activation might relate tightly to the degree of clinical improvement (YBOCS as a
169 continuous variable) or to patients’ overall well being (dichotomous responder/non-responder analysis).
170 We thus modeled each separately. We analyzed continuous YBOCS as percentage decrease from
171 baseline. Distribution fitting via the ‘fitdist’ package verified that YBOCS values were most compatible
172 with a gamma distribution. We therefore predicted YBOCS improvement via an L1-regularized
173 generalized linear regression (gamma distribution with identity link, Python package ‘pyglmnet’) and via

174 a random forest regression with 100 trees. The dependent variable was percentage improvement in
175 YBOCS. We compared these two approaches to assess whether conclusions might be sensitive to the
176 model formulation. Regularized regression emphasizes selection of a small number of highly leveraged
177 variables, which may be more helpful in defining clinical decision rules. Random forests can outperform
178 generalized linear regression in at least some cases (54), particularly where there are nonlinearities
179 better captured by thresholding.

180

181 We further analyzed categorical (non)response, defined as a 35% or greater YBOCS decrease from
182 baseline (42). For these, we compared an L1-regularized logistic regression and a random forest
183 classifier with 100 trees. A minority of visits represented clinical response (29 visits out of 165, although
184 5 of 8 patients were in clinical response during at least one visit). To compensate for this imbalance, we
185 applied the Synthetic Minority Oversampling Technique (SMOTE, (55)) with 3 nearest-neighbor
186 examples. We chose L1 regularization for both regressions because dominant models of OCD argue
187 that dysfunction in specific cortico-striatal loops leads to symptoms (21,22) and/or that a relatively small
188 number of fiber bundles can explain response (12,26–28). This should be reflected in clinical response
189 being driven a small subset of tracts.

190

191 *Data Analysis - Depression Response*

192 VCVS may have more effects on mood than on compulsivity (56), which would be reflected in better
193 prediction of mood (MADRS) than of YBOCS. We applied the modeling pipeline used for categorical
194 YBOCS response to categorical MADRS response, defined as a 50% or greater MADRS decrease
195 from pre-surgical baseline. 7 out of the 165 visits met MADRS response criteria, although this again
196 represented 5 of 8 patients.

197

198 We further assessed tractographic models' prediction of hypomania, a known and voltage-dependent
199 complication of VCVS DBS (57,68); details are in the Supplement.

200

201 *Data Analysis - Model Evaluation*

202 All categorical data sets were unbalanced, and the outcome of clinical interest was always the minority
203 class. We therefore report balanced accuracy and recall (performance for the minority class) for the
204 categorical dependent variables. Further, we report the area under the receiver operator curve (AUC),
205 which is suggested to be the best summary of a categorical biomarker's performance (36,39). For
206 continuous YBOCS prediction, we report the fraction of variance explained and the coefficient of
207 determination (R^2). We emphasize that R^2 here is not the square of a correlation coefficient (36).

208

209 All metrics were calculated on a held-out test set (36,37,39,40). For each model, we held out 2 random
210 patients from the dataset (effectively 4-fold cross-validation with resampling). This improves over leave-
211 one-out approaches, which can overstate predictive performance (58). We left out 25% of patients,
212 rather than visits, because data were highly autocorrelated visit-to-visit, which also falsely inflates
213 performance (36). We then fit the predictive model on the remaining 6 patients, and we report the
214 performance on the visit-level data from the held out patients. To prevent data leakage, the SMOTE
215 upsampling was performed on the training set only, after the split. We obtained confidence intervals for
216 all metrics by repeating this process over all 28 possible leave-two-out combinations, then calculating
217 the range of performance falling within 2 standard deviations of the median performance.

218

219 We fit 16 models (4 outcomes x 2 types of model x 2 ways of expressing activation), cross-validating
220 within each model. We interpreted the outcomes using an uncorrected 95% confidence interval to
221 maximize power.

222

223 *Data Analysis - Predictor Importance*

224 To detect potentially relevant tracts, we performed importance scoring on all models, regardless of
225 whether they correctly predicted the clinical outcomes. For regression models, we computed the
226 median and standard deviation of the regression coefficient for each tract, across all the train-test splits.
227 For random forests, we applied permutation importance as implemented in scikit-learn. We permuted
228 each independent variable 5 times for each of the train-test splits.

229

230 *Data Analysis - Alternative Univariate Approach*

231 Recent papers (12,26–28) used a different approach, based on comparison of VTAs to population-
232 scale tractography. As an additional analysis (not pre planned), we attempted a similar approach on
233 this dataset. We calculated all linear correlations between YBOCS improvement (continuous variable)
234 and the activation of each individual tract (either as a total fiber or percentage activation). These
235 correlations were performed on the training set after holding out 2 random patients, consistent with
236 (12). To test whether this approach produced more generalizable predictors of DBS response, we used
237 the same data to fit a univariate linear regression for each independent variable, then evaluated the
238 model performance (coefficient of determination, R^2) on the 2 held out patients.

239

240 In a further exploratory analysis (see Supplement), we considered whether DBS outcomes depended
241 not on the tracts activated, but the integrity of those tracts.

242 **Results**

243 *Clinical Outcomes - YBOCS*

244 The mean YBOCS improvement (considering each patient's best time point) was 46.6%, and 5 of the 8
245 patients (62.5%) were clinical responders ($\geq 35\%$ YBOCS drop) for at least one visit.

246

247 No tract reliably predicted continuous YBOCS improvement. By all metrics, model performance was
248 worse than chance on the held-out test set (Table 1), for both total-activation and percentage-activation
249 models. Consistent with this, no coefficients in the regression models were above zero (i.e., the dataset
250 mean was more reliable than any tractographic predictor). In the random forest models, the highest
251 importance was percentage activation of fibers connecting thalamus to left OFC, but this was at chance
252 level (change in R^2 across models: mean 0.09, SD 0.24).

253

254 [Table 1 about here]

255

256 Similarly, no model exceeded chance for response/nonresponse prediction (Table 2). In the logistic
257 regression, highly weighted features across models were the number (but not percentage) of activated
258 streamlines connecting thalamus to left cingulate, lateral OFC, medial OFC, and vIPFC. Cingulate and
259 lateral OFC streamline activation were positively associated with response, whereas medial OFC and
260 vIPFC activation were negatively associated (Figure 2). For all of these tracts, the confidence interval
261 for the coefficient estimated across all train-test splits included 0. These findings were sensitive to the
262 modeling approach; the same tracts did not show median importance scores different from 0 in the
263 random forest models. The ACC-PAC findings were corroborated by a Necessary Condition Analysis
264 on white matter integrity (Supplementary Results).

265

266 [Table 2 and Figure 2 about here]

267

268 The alternate mass-univariate approach also did not reliably predict response on the held-out test sets
269 (Table 3). It was concordant with the categorical response analysis in that it identified streamlines
270 connecting the left cingulate to thalamus as correlated with response, and similarly streamlines from
271 bilateral vIPFC as correlated with non-response. There was more discordance than similarity, however.
272 The medial OFC tracts identified by regression were not selected in the mass univariate approach, and
273 conversely, the mass univariate approach predicted nonresponse if tracts projecting to dIPFC were

274 within the VTA. Further, the mass univariate approach emphasized percentage capture, while the
275 logistic regression emphasized total fibers within a VTA. We note that tracts from STN to PFC were
276 negatively correlated with clinical outcomes, whereas prior reports identify them as positively correlated
277 (12,27,28).

278

279 *Clinical Outcomes - MADRS*

280 The mean MADRS improvement (considering each patient's best time point) was 55.69%, and 5 of the
281 8 (62.5%) were responders ($\geq 50\%$ MADRS drop) at some point. Mood and OCD response were not
282 linked ($r=0.13$ for correlation between response status on YBOCS and MADRS). Consistent with other
283 reports (56), there were more observations of MADRS response without YBOCS than of YBOCS
284 response without MADRS (22 vs. 4).

285

286 No model reliably predicted MADRS response above chance (Table 4). For comparison with the
287 YBOCS analysis, we further examined the non-zero coefficients of the total-fiber regression. Capture of
288 streamlines between right cingulate and thalamus was correlated with MADRS response, and the
289 confidence interval for this coefficient excluded zero (Figure 3). This was not true of any other tract. Left
290 vIPFC was associated with non-response (as it was in the categorical YBOCS analysis), but the
291 distribution of coefficients across analyses included zero. Random forest importance scores were
292 centered around zero.

293

294 [Table 4 and Figure 3 about here]

295

296 **Discussion**

297 Our results are both concordant and discordant with prior efforts to predict clinical OCD DBS response
298 from tractographic modeling of cortico-striatal and cortico-basal circuits. Critically, we implemented

299 multiple analytic steps beyond prior studies: individualized, patient-specific tracts registered to
300 individual lead placements, activation volume calculation beyond simple electric field assumptions,
301 consideration of multiple clinical timepoints for each patient, and formal evaluation of predictive power
302 (as compared to measurement of correlations between activation and response or group mean
303 differences). With this more guideline-adherent approach, we found that no tract could reliably predict
304 clinical response or complications, whether those were considered in a continuous or categorical
305 approach. This is likely not a surprise – we and others have highlighted that group-level significant
306 correlations/separations often do not have clinical predictive power (36–39). In this sense, our results
307 support calls for caution regarding the clinical role of tractography (16,41). We also showed that
308 outcomes can be sensitive to the analytic approach – our random forest and regularized regression
309 approaches produced very different results, even though both are commonly used approaches to
310 prediction and variable selection.

311

312 Model inspection may offer some insight into variables for further investigation, even if pathway
313 activation modeling approaches are not yet able to strongly predict response. Numerically, predictive
314 power was greater (more non-zero regression coefficients after regularization) when predicting
315 categorical rather than continuous outcomes. This may be because categorical outcomes effectively
316 smooth out small fluctuations in continuous rating scales, fluctuations that may be primarily due to inter-
317 rater variability or disease-unrelated variables rather than to DBS settings. The YBOCS in particular
318 shows non-linear behavior at high scores that may exacerbate this (59). We obtained non-zero
319 regression coefficients for models using activated fiber counts, but not for percentage-activated models,
320 implying that it is more important to get at least a portion of a key tract within the VTA. These results
321 also make sense in the context of our finding that the integrity (traceability) of these tracts varies greatly
322 between patients with OCD -- a tract where response depends on tract integrity will have a large
323 coefficient in a total-fibers model, but not in a percentage-activation model.

324

325 Our results in part support and in part diverge from a series of recent papers implicating pathways
326 between PFC and basal ganglia as critical for OCD DBS (12,26–28). Consistent with that work, the
327 ACC/PAC to thalamus tracts were implicated in both YBOCS and MADRS response, and were the
328 most positively weighted in our mass-univariate approach. Our white matter integrity analysis identified
329 the same tracts as having the largest effect size (necessity). Also similar to that prior work, we found
330 that activation of connections to medial OFC produced numerically worse outcomes. Inconsistent with
331 the prior work (12,26–28), we found negative correlations (in the mass univariate analysis) or null
332 effects (in the predictive models) specifically for tracts connecting PFC to STN or vIPFC to thalamus.
333 This again may reflect the importance of patient-specific imaging. Given that we have previously shown
334 these tracts to have substantial inter-individual variability in their position within the internal capsule
335 (33), and that here we note them to have similar variability in their overall integrity, a normative
336 connectomic analysis may not reflect the actual fibers being successfully modulated in DBS cases.
337 Alternatively, our results may highlight programming and surgical differences. These patients were
338 implanted and programmed following the approach in (60), which emphasizes an initial search for a
339 positive affective response. Other centers have reported very different programming algorithms (61),
340 based more on standard anatomic positions. If response correlates with, e.g., the quality of concomitant
341 therapy (26,62) or general clinical expertise (63), those factors will likely be strongly correlated with the
342 programming clinician, and thus will spuriously load onto the tracts and implant locations that clinician
343 happens to prefer. Most importantly, our results highlight the importance of applying analyses designed
344 specifically to identify clinical predictors (36). Interestingly, we found that OFC engagement predicted
345 worse OCD clinical response. OFC-originating components of cortico-striato-thalamic circuits are
346 heavily emphasized in theoretical (21,22,29) and animal (30,32,64) models of OCD, and these findings
347 may contribute to an ongoing debate over those models.

348

349 These results are tempered by three limitations. First, our sample size is small, consistent with the rarity
350 of these patients (65). Second, imaging was not performed on a connectome-optimized scanner, and
351 scanning at 7 Tesla (as has now become more common (66)) might identify more tracts. Third, we used

352 relatively simple models of DBS activation. All of these add noise, reducing our ability to detect subtle
353 correlations, particularly given DTI's susceptibility to false positives (14). Practically, however, these
354 limitations may not affect the clinical importance of our findings. We mitigated the lower resolution of
355 these scans by use of an algorithm that is specifically designed to perform well in the presence of noise
356 (45) and ensuring that our extracted tracts matched known, anatomically verified fiber bundles (48).
357 Further, small sample sizes tend to inflate effect sizes and bias towards positive conclusions (67), not
358 the negative result we report. Most importantly, for a tractographic result to be sufficiently reliable to
359 inform clinical targeting/programming, it would need to have a large and clear influence on outcomes,
360 with robustness to minor variations in analytic or clinical technique. Such a large effect would be clearly
361 detectable and consistent across studies even at small sample sizes, like the clinical effect of VCVS
362 DBS, which shows consistent 60-70% response rates across many small to medium cohorts (56,68–
363 71). In that context, failure to identify a significant predictor in this small sample is relevant to both
364 clinical practice and future study design.

365

366 Overall, our results support a growing argument that circuits linking ACC to thalamus and basal ganglia
367 are important to VCVS DBS response. They dovetail with other work linking modulation of those circuits
368 to increased cognitive control (72,73), a construct that is thought to be deficient in OCD (74,75). At the
369 same time, they highlight that the current level of tractographic understanding does not have strong
370 clinical predictive power, and that multiple confounds remain to be controlled/addressed. With multiple
371 technologies emerging to better verify target engagement and address patient heterogeneity (1,16),
372 that understanding will likely grow in coming years.

373

374 **Data/Code Availability**

375 De-identified data tables and analysis code used to produce all exhibits in this manuscript will be
376 available at the time of publication at <https://github.com/tne-lab> .

377

378 **Acknowledgements**

379 This work was supported by NIH grants R03MH111320 (ASW, CCM, DDD), UH3NS100548 (ASW,
380 DDD), R01MH111917 (ASW, DDD, NMM, YR), U01U01MH076179 (BDG), P20GM130452 (NCM,
381 BDG), K23MH100607 (NCM), and P50MH106435 (NCM, BDG). ASW further acknowledges support
382 from the MnDRIVE Brain Conditions and Minnesota Medical Discovery Team – Addictions initiatives.
383 All opinions and conclusions herein are those of the authors. They do not represent the views or official
384 policy of any public or private funding body.

385

386 **Disclosures**

387 ASW and DDD have received research funding, device donations, and honoraria from Medtronic, which
388 manufactured the DBS devices used in patients' clinical care. Medtronic had no financial or technical
389 role in this study. ASW and CCM have multiple patents and patent filings in the area of deep brain
390 stimulation, including methods for optimizing/customizing stimulation parameters. CCM is a paid
391 consultant for Boston Scientific Neuromodulation, receives royalties from Hologram Consultants,
392 Neuros Medical, Qr8 Health, and is a shareholder in the following companies: Hologram Consultants,
393 Surgical Information Sciences, CereGate, Autonomic Technologies, Cardionomic, and Enspire DBS. All
394 other authors affirm no related financial interests.

395

396 **References**

- 397 1. Sullivan CRP, Olsen S, Widge AS (2021): Deep brain stimulation for psychiatric disorders: From
398 focal brain targets to cognitive networks. *NeuroImage* 225: 117515.
- 399 2. Bari AA, Mikell CB, Abosch A, Ben-Haim S, Buchanan RJ, Burton AW, *et al.* (2018): Charting the
400 road forward in psychiatric neurosurgery: proceedings of the 2016 American Society for
401 Stereotactic and Functional Neurosurgery workshop on neuromodulation for psychiatric
402 disorders. *J Neurol Neurosurg Psychiatry* jnnp-2017-317082.

- 403 3. Ramirez-Zamora A, Giordano J, Gunduz A, Alcantara J, Cagle JN, Cerner S, *et al.* (2020):
404 Proceedings of the Seventh Annual Deep Brain Stimulation Think Tank: Advances in
405 Neurophysiology, Adaptive DBS, Virtual Reality, Neuroethics and Technology. *Front Hum*
406 *Neurosci* 14: 54.
- 407 4. Widge AS, Malone DAJ, Dougherty DD (2018): Closing the loop on deep brain stimulation for
408 treatment-resistant depression. *Front Neurosci* 12: 175.
- 409 5. Luyten L, Hendrickx S, Raymaekers S, Gabriëls L, Nuttin B (2016): Electrical stimulation in the bed
410 nucleus of the stria terminalis alleviates severe obsessive-compulsive disorder. *Mol Psychiatry*
411 21: 1272–1280.
- 412 6. Holtzheimer PE, Husain MM, Lisanby SH, Taylor SF, Whitworth LA, McClintock S, *et al.* (2017):
413 Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite,
414 randomised, sham-controlled trial. *Lancet Psychiatry* 4: 839–849.
- 415 7. Dougherty DD, Rezai AR, Carpenter LL, Howland RH, Bhati MT, O'Reardon JP, *et al.* (2015): A
416 randomized sham-controlled trial of deep brain stimulation of the ventral capsule/ventral
417 striatum for chronic treatment-resistant depression. *Biol Psychiatry* 78: 240–248.
- 418 8. Williams LM (2016): Defining biotypes for depression and anxiety based on large-scale circuit
419 dysfunction: a theoretical review of the evidence and future directions for clinical translation.
420 *Depress Anxiety* 34: 9–24.
- 421 9. Avena-Koenigsberger A, Misic B, Sporns O (2018): Communication dynamics in complex brain
422 networks. *Nat Rev Neurosci* 19: 17.
- 423 10. Riva-Posse P, Choi KS, Holtzheimer PE, Crowell AL, Garlow SJ, Rajendra JK, *et al.* (2018): A
424 connectomic approach for subcallosal cingulate deep brain stimulation surgery: prospective
425 targeting in treatment-resistant depression. *Mol Psychiatry* 23: 843–849.
- 426 11. Karas PJ, Lee S, Jimenez-Shahed J, Goodman WK, Viswanathan A, Sheth SA (2019): Deep brain
427 stimulation for obsessive compulsive disorder: evolution of surgical stimulation target parallels
428 changing model of dysfunctional brain circuits. *Front Neurosci* 12: 998.

- 429 12. Li N, Baldermann JC, Kibleur A, Treu S, Akram H, Elias GJB, *et al.* (2020): A unified connectomic
430 target for deep brain stimulation in obsessive-compulsive disorder [no. 1]. *Nat Commun* 11:
431 3364.
- 432 13. Maier-Hein KH, Neher PF, Houde J-C, Côté M-A, Garyfallidis E, Zhong J, *et al.* (2017): The
433 challenge of mapping the human connectome based on diffusion tractography [no. 1]. *Nat*
434 *Commun* 8: 1349.
- 435 14. Haber SN, Tang W, Choi EY, Yendiki A, Liu H, Jbabdi S, *et al.* (2020): Circuits, networks, and
436 neuropsychiatric disease: transitioning from anatomy to imaging. *Biol Psychiatry* 87: 318–327.
- 437 15. Noecker AM, Choi KS, Riva-Posse P, Gross RE, Mayberg HS, McIntyre CC (2018): StimVision
438 software: examples and applications in subcallosal cingulate deep brain stimulation for
439 depression. *Neuromodulation Technol Neural Interface* 21: 191–196.
- 440 16. Noecker AM, Frankemolle-Gilbert AM, Howell B, Petersen MV, Beylergil SB, Shaikh AG, McIntyre
441 CC (2021): StimVision v2: examples and applications in subthalamic deep brain stimulation for
442 parkinson's disease. *Neuromodulation Technol Neural Interface* 24: 248–258.
- 443 17. Horn A, Kühn AA (2015): Lead-DBS: A toolbox for deep brain stimulation electrode localizations
444 and visualizations. *NeuroImage* 107: 127–135.
- 445 18. Peña E, Zhang S, Patriat R, Aman JE, Vitek JL, Harel N, Johnson MD (2018): Multi-objective
446 particle swarm optimization for postoperative deep brain stimulation targeting of subthalamic
447 nucleus pathways. *J Neural Eng* 15: 066020.
- 448 19. Provenza NR, Matteson ER, Allawala AB, Barrios-Anderson A, Sheth SA, Viswanathan A, *et al.*
449 (2019): The case for adaptive neuromodulation to treat severe intractable mental disorders.
450 *Front Neurosci* 13. <https://doi.org/10.3389/fnins.2019.00152>
- 451 20. Ramasubbu R, Clark DL, Golding S, Dobson KS, Mackie A, Haffenden A, Kiss ZH (2020): Long
452 versus short pulse width subcallosal cingulate stimulation for treatment-resistant depression: a
453 randomised, double-blind, crossover trial. *Lancet Psychiatry* 7: 29–40.
- 454 21. Robbins TW, Vaghi MM, Banca P (2019): Obsessive-compulsive disorder: puzzles and prospects.
455 *Neuron* 102: 27–47.

- 456 22. Dougherty DD, Brennan B, Stewart SE, Wilhelm S, Widge AS, Rauch SL (2018): Neuroscientifically
457 informed formulation and treatment planning for patients with obsessive-compulsive disorder: a
458 review. *JAMA Psychiatry* 75: 1081–1087.
- 459 23. Hartmann CJ, Lujan JL, Chaturvedi A, Goodman WK, Okun MS, McIntyre CC, Haq IU (2016):
460 Tractography activation patterns in dorsolateral prefrontal cortex suggest better clinical
461 responses in OCD DBS. *Neuroprosthetics* 519.
- 462 24. Baldermann JC, Melzer C, Zapf A, Kohl S, Timmermann L, Tittgemeyer M, *et al.* (2019):
463 Connectivity profile predictive of effective deep brain stimulation in obsessive-compulsive
464 disorder. *Biol Psychiatry* 85: 735–743.
- 465 25. Barcia JA, Avecillas-Chasín JM, Nombela C, Arza R, Albea JG-, Pineda J-Á, *et al.* (2018):
466 Personalized striatal targets for deep brain stimulation in obsessive-compulsive disorder. *Brain*
467 *Stimulat*. <https://doi.org/10.1016/j.brs.2018.12.226>
- 468 26. Mosley PE, Windels F, Morris J, Coyne T, Marsh R, Giorni A, *et al.* (2021): A randomised, double-
469 blind, sham-controlled trial of deep brain stimulation of the bed nucleus of the stria terminalis for
470 treatment-resistant obsessive-compulsive disorder [no. 1]. *Transl Psychiatry* 11: 1–17.
- 471 27. Smith AH, Choi KS, Waters AC, Aloysi A, Mayberg HS, Kopell BH, Figeo M (2021): Replicable
472 effects of deep brain stimulation for obsessive-compulsive disorder. *Brain Stimulat* 14: 1–3.
- 473 28. Bouwens van der Vlis TAM, Ackermans L, Mulders AEP, Vrij CA, Schruers K, Temel Y, *et al.* (n.d.):
474 Ventral capsule/ventral striatum stimulation in obsessive-compulsive disorder: toward a unified
475 connectomic target for deep brain stimulation? *Neuromodulation Technol Neural Interface* n/a.
476 <https://doi.org/10.1111/ner.13339>
- 477 29. Haber SN, Yendiki A, Jbabdi S (2020): Four deep brain stimulation targets for obsessive-
478 compulsive disorder: Are they different? *Biol Psychiatry* S000632232031773X.
- 479 30. Wood J, Ahmari SE (2015): A framework for understanding the emerging role of corticolimbic-
480 ventral striatal networks in OCD-associated repetitive behaviors. *Front Syst Neurosci* 171.
- 481 31. Burguière E, Monteiro P, Feng G, Graybiel AM (2013): Optogenetic stimulation of lateral
482 orbitofronto-striatal pathway suppresses compulsive behaviors. *Science* 340: 1243–1246.

- 483 32. Heilbronner SR, Rodriguez-Romaguera J, Quirk GJ, Groenewegen HJ, Haber SN (2016): Circuit
484 based cortico-striatal homologies between rat and primate. *Biol Psychiatry* 80: 509–521.
- 485 33. Makris N, Rathi Y, Mouradian P, Bonmassar G, Papadimitriou G, Ing WI, *et al.* (2016): Variability
486 and anatomical specificity of the orbitofrontothalamic fibers of passage in the ventral
487 capsule/ventral striatum (VC/VS): precision care for patient-specific tractography-guided
488 targeting of deep brain stimulation (DBS) in obsessive compulsive disorder (OCD). *Brain*
489 *Imaging Behav* 10: 1054–1067.
- 490 34. Liebrand LC, Caan MWA, Schuurman PR, van den Munckhof P, Figeo M, Denys D, van Wingen
491 GA (2018): Individual white matter bundle trajectories are associated with deep brain stimulation
492 response in obsessive-compulsive disorder. *Brain Stimulat.*
493 <https://doi.org/10.1016/j.brs.2018.11.014>
- 494 35. Howell B, McIntyre CC (2016): Analyzing the tradeoff between electrical complexity and accuracy in
495 patient-specific computational models of deep brain stimulation. *J Neural Eng* 13: 036023.
- 496 36. Poldrack RA, Huckins G, Varoquaux G (2020): Establishment of best practices for evidence for
497 prediction: a review. *JAMA Psychiatry* 77: 534–540.
- 498 37. Grzenda A, Kraguljac NV, McDonald WM, Nemeroff CB, Torous J, Alpert JE, *et al.* (Accepted):
499 Evaluating the machine learning literature: a primer and user’s guide for psychiatrists. *Am J*
500 *Psychiatry*.
- 501 38. Lo A, Chernoff H, Zheng T, Lo S-H (2015): Why significant variables aren’t automatically good
502 predictors. *Proc Natl Acad Sci* 112: 13892–13897.
- 503 39. Widge AS, Bilge MT, Montana R, Chang W, Rodriguez CI, Deckersbach T, *et al.* (2019):
504 Electroencephalographic biomarkers for treatment response prediction in major depressive
505 illness: a meta-analysis. *Am J Psychiatry* 176: 44–56.
- 506 40. Woo C-W, Chang LJ, Lindquist MA, Wager TD (2017): Building better biomarkers: brain models in
507 translational neuroimaging. *Nat Neurosci* 20: 365–377.

- 508 41. Coenen VA, Schlaepfer TE, Varkuti B, Schuurman PR, Reinacher PC, Voges J, *et al.* (2019):
509 Surgical decision making for deep brain stimulation should not be based on aggregated
510 normative data mining. *Brain Stimul Basic Transl Clin Res Neuromodulation* 12: 1345–1348.
- 511 42. McLaughlin N, Dougherty DD, Eskandar EN, Ward HE, Foote KD, Malone Jr. DA, *et al.* (n.d.):
512 Double blind randomized controlled trial of deep brain stimulation for obsessive-compulsive
513 disorder: clinical trial design. *Contemp Clin Trials*.
- 514 43. reckbo, Tashrif Billah, Isaiah Norton (2019): *Pnlbwh/Pnlpipe: Easy Install and Multiprocessing*.
515 Zenodo. <https://doi.org/10.5281/zenodo.3270927>
- 516 44. Malcolm JG, Shenton ME, Rathi Y (2010): Filtered multitensor tractography [no. 9]. *IEEE Trans*
517 *Med Imaging* 29: 1664–1675.
- 518 45. Reddy CP, Rathi Y (2016): Joint Multi-Fiber NODDI Parameter Estimation and Tractography Using
519 the Unscented Information Filter. *Front Neurosci* 10. <https://doi.org/10.3389/fnins.2016.00166>
- 520 46. Gong S, Zhang F, Norton I, Essayed WI, Unadkat P, Rigolo L, *et al.* (2018): Free water modeling of
521 peritumoral edema using multi-fiber tractography: Application to tracking the arcuate fasciculus
522 for neurosurgical planning [no. 5]. *PLoS ONE* 13. <https://doi.org/10.1371/journal.pone.0197056>
- 523 47. Liao R, Ning L, Chen Z, Rigolo L, Gong S, Pasternak O, *et al.* (2017): Performance of unscented
524 Kalman filter tractography in edema: Analysis of the two-tensor model. *NeuroImage Clin* 15:
525 819–831.
- 526 48. Zhang F, Wu Y, Norton I, Rigolo L, Rathi Y, Makris N, O'Donnell LJ (2018): An anatomically curated
527 fiber clustering white matter atlas for consistent white matter tract parcellation across the
528 lifespan. *NeuroImage* 179: 429–447.
- 529 49. Chen Z, Tie Y, Olubiyi O, Rigolo L, Mehrtash A, Norton I, *et al.* (2015): Reconstruction of the
530 arcuate fasciculus for surgical planning in the setting of peritumoral edema using two-tensor
531 unscented Kalman filter tractography. *NeuroImage Clin* 7: 815–822.
- 532 50. Chaturvedi A, Luján JL, McIntyre CC (2013): Artificial neural network based characterization of the
533 volume of tissue activated during deep brain stimulation. *J Neural Eng* 10: 056023.

- 534 51. Butson CR, McIntyre CC (2006): Role of electrode design on the volume of tissue activated during
535 deep brain stimulation. *J Neural Eng* 3: 1–8.
- 536 52. O'Donnell LJ, Westin C-F (2007): Automatic tractography segmentation using a high-dimensional
537 white matter atlas [no. 11]. *IEEE Trans Med Imaging* 26: 1562–1575.
- 538 53. O'Donnell LJ, Wells WM, Golby AJ, Westin C-F (2012): Unbiased groupwise registration of white
539 matter tractography. In: Ayache N, Delingette H, Golland P, Mori K, editors. *Medical Image*
540 *Computing and Computer-Assisted Intervention – MICCAI 2012*, vol. 7512. Berlin, Heidelberg:
541 Springer Berlin Heidelberg, pp 123–130.
- 542 54. Couronné R, Probst P, Boulesteix A-L (2018): Random forest versus logistic regression: a large-
543 scale benchmark experiment. *BMC Bioinformatics* 19: 270.
- 544 55. Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP (2002): SMOTE: Synthetic Minority Over-
545 sampling Technique. *J Artif Intell Res* 16: 321–357.
- 546 56. Tyagi H, Apergis-Schoute AM, Akram H, Foltynie T, Limousin P, Drummond LM, *et al.* (2019): A
547 randomised trial directly comparing ventral capsule and anteromedial subthalamic nucleus
548 stimulation in obsessive compulsive disorder: clinical and imaging evidence for dissociable
549 effects. *Biol Psychiatry* 85: 726–734.
- 550 57. Widge AS, Licon E, Zorowitz S, Corse A, Arulpragasam AR, Camprodon JA, *et al.* (2015):
551 Predictors of hypomania during ventral capsule/ventral striatum deep brain stimulation. *J*
552 *Neuropsychiatry Clin Neurosci* 28: 38–44.
- 553 58. Smith GCS, Seaman SR, Wood AM, Royston P, White IR (2014): Correcting for optimistic
554 prediction in small data sets. *Am J Epidemiol* 180: 318–324.
- 555 59. Storch EA, Rasmussen SA, Price LH, Larson MJ, Murphy TK, Goodman WK (2010): Development
556 and psychometric evaluation of the Yale–Brown Obsessive-Compulsive Scale—Second Edition.
557 *Psychol Assess* 22: 223.
- 558 60. Widge AS, Dougherty DD (2015): Managing patients with psychiatric disorders with deep brain
559 stimulation. In: Marks Jr. WJ, editor. *Deep Brain Stimulation Management*, 2nd ed. Cambridge :
560 New York: Cambridge University Press.

- 561 61. van Westen M, Rietveld E, Bergfeld IO, Koning P de, Vullink N, Ooms P, *et al.* (2021): Optimizing
562 deep brain stimulation parameters in obsessive–compulsive disorder. *Neuromodulation Technol*
563 *Neural Interface* 24: 307–315.
- 564 62. Mantione M, Nieman DH, Figeo M, Denys D (2014): Cognitive–behavioural therapy augments the
565 effects of deep brain stimulation in obsessive–compulsive disorder. *Psychol Med* 44: 3515–
566 3522.
- 567 63. van Westen M, Rietveld E, Denys D (2019): Effective deep brain stimulation for obsessive-
568 compulsive disorder requires clinical expertise. *Front Psychol* 10: 2294.
- 569 64. Burguière E, Monteiro P, Mallet L, Feng G, Graybiel AM (2015): Striatal circuits, habits, and
570 implications for obsessive–compulsive disorder. *Curr Opin Neurobiol* 30: 59–65.
- 571 65. Garnaat SL, Greenberg BD, Sibrava NJ, Goodman WK, Mancebo MC, Eisen JL, Rasmussen SA
572 (2014): Who qualifies for deep brain stimulation for OCD? Data from a naturalistic clinical
573 sample. *J Neuropsychiatry Clin Neurosci* 26: 81–86.
- 574 66. Duchin Y, Shamir RR, Patriat R, Kim J, Vitek JL, Sapiro G, Harel N (2018): Patient-specific
575 anatomical model for deep brain stimulation based on 7 Tesla MRI. *PLoS One* 13: e0201469.
- 576 67. Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, Munafò MR (2013): Power
577 failure: why small sample size undermines the reliability of neuroscience. *Nat Rev Neurosci* 14:
578 365–376.
- 579 68. Denys D, Graat I, Mocking R, de Koning P, Vullink N, Figeo M, *et al.* (2020): Efficacy of deep brain
580 stimulation of the ventral anterior limb of the internal capsule for refractory obsessive-
581 compulsive disorder: a clinical cohort of 70 patients. *Am J Psychiatry* appi.ajp.2019.19060656.
- 582 69. Menchón JM, Real E, Alonso P, Aparicio MA, Segalas C, Plans G, *et al.* (2021): A prospective
583 international multi-center study on safety and efficacy of deep brain stimulation for resistant
584 obsessive-compulsive disorder [no. 4]. *Mol Psychiatry* 26: 1234–1247.
- 585 70. Greenberg B, Gabriels L, Malone D, Rezai A, Friehs G, Okun M, *et al.* (2010): Deep brain
586 stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder:
587 worldwide experience. *Mol Psychiatry* 15: 64–79.

- 588 71. Nuttin B, Cosyns P, Demeulemeester H, Gybels J, Meyerson B (1999): Electrical stimulation in
589 anterior limbs of internal capsules in patients with obsessive-compulsive disorder. *The Lancet*
590 354: 1526.
- 591 72. Basu I, Yousefi A, Crocker B, Zelmann R, Paulk AC, Peled N, *et al.* (Accepted in principle): Closed
592 loop enhancement and neural decoding of human cognitive control. *Nat Biomed Eng.*
593 <https://doi.org/10.1101/2020.04.24.059964>
- 594 73. Widge AS, Zorowitz S, Basu I, Paulk AC, Cash SS, Eskandar EN, *et al.* (2019): Deep brain
595 stimulation of the internal capsule enhances human cognitive control and prefrontal cortex
596 function. *Nat Commun* 10: 1536.
- 597 74. Gruner P, Pittenger C (2017): Cognitive inflexibility in Obsessive-Compulsive Disorder.
598 *Neuroscience* 345: 243–255.
- 599 75. Abramovitch A, Abramowitz JS, Mittelman A (2013): The neuropsychology of adult obsessive–
600 compulsive disorder: A meta-analysis. *Clin Psychol Rev* 33: 1163–1171.
- 601 76. Brennan BP, Jacoby RJ, Widge AS (2018): A case of severe intractable contamination-based
602 obsessive-compulsive disorder. *JAMA Psychiatry* 75: 1088–1089.
- 603 77. Smith SM (2002): Fast robust automated brain extraction [no. 3]. *Hum Brain Mapp* 17: 143–155.
- 604 78. Jenkinson M, Pechaud M, Smith S (2005): BET2 - MR-Based Estimation of Brain, Skull and Scalp
605 Surfaces. presented at the Eleventh Annual Meeting of the Organization for Human Brain
606 Mapping. Retrieved from <http://mickaelpechaud.free.fr/these/HBM05.pdf>
- 607 79. *Advanced Normalization Tools (ANTs)* (2021): Advanced Normalization Tools Ecosystem.
608 Retrieved April 1, 2021, from <https://github.com/ANTsX/ANTs>
- 609 80. Howell B, Choi KS, Gunalan K, Rajendra J, Mayberg HS, McIntyre CC (2019): Quantifying the
610 axonal pathways directly stimulated in therapeutic subcallosal cingulate deep brain stimulation.
611 *Hum Brain Mapp* 40: 889–903.
- 612 81. Dul J (2016): Necessary Condition Analysis (NCA): logic and methodology of “necessary but not
613 sufficient” causality. *Organ Res Methods* 19: 10–52.

- 614 82. Dul J (2021): *NCA: Necessary Condition Analysis*, version 3.1.0. Retrieved April 1, 2021, from
615 <https://CRAN.R-project.org/package=NCA>
616
- 617 2. Bari AA, Mikell CB, Abosch A, Ben-Haim S, Buchanan RJ, Burton AW, *et al.* (2018): Charting the
618 road forward in psychiatric neurosurgery: proceedings of the 2016 American Society for
619 Stereotactic and Functional Neurosurgery workshop on neuromodulation for psychiatric
620 disorders. *J Neurol Neurosurg Psychiatry* jnnp-2017-317082.
- 621 3. Ramirez-Zamora A, Giordano J, Gunduz A, Alcantara J, Cagle JN, Cerner S, *et al.* (2020):
622 Proceedings of the Seventh Annual Deep Brain Stimulation Think Tank: Advances in
623 Neurophysiology, Adaptive DBS, Virtual Reality, Neuroethics and Technology. *Front Hum*
624 *Neurosci* 14: 54.
- 625 4. Widge AS, Malone DAJ, Dougherty DD (2018): Closing the loop on deep brain stimulation for
626 treatment-resistant depression. *Front Neurosci* 12: 175.
- 627 5. reckbo, Tashrif Billah, Isaiah Norton (2019): *Pnlbwh/Pnlpipe: Easy Install and Multiprocessing*.
628 Zenodo. <https://doi.org/10.5281/zenodo.3270927>
- 629 6. Luyten L, Hendrickx S, Raymaekers S, Gabriëls L, Nuttin B (2016): Electrical stimulation in the bed
630 nucleus of the stria terminalis alleviates severe obsessive-compulsive disorder. *Mol Psychiatry*
631 21: 1272–1280.
- 632 7. Widge AS, Licon E, Zorowitz S, Corse A, Arulpragasam AR, Camprodon JA, *et al.* (2015): Predictors
633 of hypomania during ventral capsule/ventral striatum deep brain stimulation. *J Neuropsychiatry*
634 *Clin Neurosci* 28: 38–44.
- 635 8. Holtzheimer PE, Husain MM, Lisanby SH, Taylor SF, Whitworth LA, McClintock S, *et al.* (2017):
636 Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite,
637 randomised, sham-controlled trial. *Lancet Psychiatry* 4: 839–849.
- 638 9. Denys D, Graat I, Mocking R, de Koning P, Vulink N, Figeet M, *et al.* (2020): Efficacy of deep brain
639 stimulation of the ventral anterior limb of the internal capsule for refractory obsessive-
640 compulsive disorder: a clinical cohort of 70 patients. *Am J Psychiatry* appi.ajp.2019.19060656.

- 641 10. Dougherty DD, Rezai AR, Carpenter LL, Howland RH, Bhati MT, O'Reardon JP, *et al.* (2015): A
642 randomized sham-controlled trial of deep brain stimulation of the ventral capsule/ventral
643 striatum for chronic treatment-resistant depression. *Biol Psychiatry* 78: 240–248.
- 644 11. Williams LM (2016): Defining biotypes for depression and anxiety based on large-scale circuit
645 dysfunction: a theoretical review of the evidence and future directions for clinical translation.
646 *Depress Anxiety* 34: 9–24.
- 647 12. Avena-Koenigsberger A, Misic B, Sporns O (2018): Communication dynamics in complex brain
648 networks. *Nat Rev Neurosci* 19: 17.
- 649 13. Riva-Posse P, Choi KS, Holtzheimer PE, Crowell AL, Garlow SJ, Rajendra JK, *et al.* (2018): A
650 connectomic approach for subcallosal cingulate deep brain stimulation surgery: prospective
651 targeting in treatment-resistant depression. *Mol Psychiatry* 23: 843–849.
- 652 14. Karas PJ, Lee S, Jimenez-Shahed J, Goodman WK, Viswanathan A, Sheth SA (2019): Deep brain
653 stimulation for obsessive compulsive disorder: evolution of surgical stimulation target parallels
654 changing model of dysfunctional brain circuits. *Front Neurosci* 12: 998.
- 655 15. Li N, Baldermann JC, Kibleur A, Treu S, Akram H, Elias GJB, *et al.* (2020): A unified connectomic
656 target for deep brain stimulation in obsessive-compulsive disorder [no. 1]. *Nat Commun* 11:
657 3364.
- 658 16. Maier-Hein KH, Neher PF, Houde J-C, Côté M-A, Garyfallidis E, Zhong J, *et al.* (2017): The
659 challenge of mapping the human connectome based on diffusion tractography [no. 1]. *Nat*
660 *Commun* 8: 1349.
- 661 17. Haber SN, Tang W, Choi EY, Yendiki A, Liu H, Jbabdi S, *et al.* (2020): Circuits, networks, and
662 neuropsychiatric disease: transitioning from anatomy to imaging. *Biol Psychiatry* 87: 318–327.
- 663 18. Noecker AM, Choi KS, Riva-Posse P, Gross RE, Mayberg HS, McIntyre CC (2018): StimVision
664 software: examples and applications in subcallosal cingulate deep brain stimulation for
665 depression. *Neuromodulation Technol Neural Interface* 21: 191–196.

- 666 19. Noecker AM, Frankemolle-Gilbert AM, Howell B, Petersen MV, Beylergil SB, Shaikh AG, McIntyre
667 CC (2021): StimVision v2: examples and applications in subthalamic deep brain stimulation for
668 parkinson's disease. *Neuromodulation Technol Neural Interface* 24: 248–258.
- 669 20. Horn A, Kühn AA (2015): Lead-DBS: A toolbox for deep brain stimulation electrode localizations
670 and visualizations. *NeuroImage* 107: 127–135.
- 671 21. Peña E, Zhang S, Patriat R, Aman JE, Vitek JL, Harel N, Johnson MD (2018): Multi-objective
672 particle swarm optimization for postoperative deep brain stimulation targeting of subthalamic
673 nucleus pathways. *J Neural Eng* 15: 066020.
- 674 22. Provenza NR, Matteson ER, Allawala AB, Barrios-Anderson A, Sheth SA, Viswanathan A, *et al.*
675 (2019): The case for adaptive neuromodulation to treat severe intractable mental disorders.
676 *Front Neurosci* 13. <https://doi.org/10.3389/fnins.2019.00152>
- 677 23. Ramasubbu R, Clark DL, Golding S, Dobson KS, Mackie A, Haffenden A, Kiss ZH (2020): Long
678 versus short pulse width subcallosal cingulate stimulation for treatment-resistant depression: a
679 randomised, double-blind, crossover trial. *Lancet Psychiatry* 7: 29–40.
- 680 24. Robbins TW, Vaghi MM, Banca P (2019): Obsessive-compulsive disorder: puzzles and prospects.
681 *Neuron* 102: 27–47.
- 682 25. Dougherty DD, Brennan B, Stewart SE, Wilhelm S, Widge AS, Rauch SL (2018): Neuroscientifically
683 informed formulation and treatment planning for patients with obsessive-compulsive disorder: a
684 review. *JAMA Psychiatry* 75: 1081–1087.
- 685 26. Hartmann CJ, Lujan JL, Chaturvedi A, Goodman WK, Okun MS, McIntyre CC, Haq IU (2016):
686 Tractography activation patterns in dorsolateral prefrontal cortex suggest better clinical
687 responses in OCD DBS. *Neuroprosthetics* 519.
- 688 27. Baldermann JC, Melzer C, Zapf A, Kohl S, Timmermann L, Tittgemeyer M, *et al.* (2019):
689 Connectivity profile predictive of effective deep brain stimulation in obsessive-compulsive
690 disorder. *Biol Psychiatry* 85: 735–743.


- 691 28. Barcia JA, Avecillas-Chasín JM, Nombela C, Arza R, Albea JG-, Pineda J-Á, *et al.* (2018):
692 Personalized striatal targets for deep brain stimulation in obsessive-compulsive disorder. *Brain*
693 *Stimulat*. <https://doi.org/10.1016/j.brs.2018.12.226>
- 694 29. Mosley PE, Windels F, Morris J, Coyne T, Marsh R, Giorni A, *et al.* (2021): A randomised, double-
695 blind, sham-controlled trial of deep brain stimulation of the bed nucleus of the stria terminalis for
696 treatment-resistant obsessive-compulsive disorder [no. 1]. *Transl Psychiatry* 11: 1–17.
- 697 30. Smith AH, Choi KS, Waters AC, Aloysi A, Mayberg HS, Kopell BH, Figuee M (2021): Replicable
698 effects of deep brain stimulation for obsessive-compulsive disorder. *Brain Stimulat* 14: 1–3.
- 699 31. Bouwens van der Vlis TAM, Ackermans L, Mulders AEP, Vrij CA, Schruers K, Temel Y, *et al.* (n.d.):
700 Ventral capsule/ventral striatum stimulation in obsessive-compulsive disorder: toward a unified
701 connectomic target for deep brain stimulation? *Neuromodulation Technol Neural Interface* n/a.
702 <https://doi.org/10.1111/ner.13339>
- 703 32. Haber SN, Yendiki A, Jbabdi S (2020): Four deep brain stimulation targets for obsessive-
704 compulsive disorder: Are they different? *Biol Psychiatry* S000632232031773X.
- 705 33. Wood J, Ahmari SE (2015): A framework for understanding the emerging role of corticolimbic-
706 ventral striatal networks in OCD-associated repetitive behaviors. *Front Syst Neurosci* 171.
- 707 34. Burguière E, Monteiro P, Feng G, Graybiel AM (2013): Optogenetic stimulation of lateral
708 orbitofronto-striatal pathway suppresses compulsive behaviors. *Science* 340: 1243–1246.
- 709 35. Heilbronner SR, Rodriguez-Romaguera J, Quirk GJ, Groenewegen HJ, Haber SN (2016): Circuit
710 based cortico-striatal homologies between rat and primate. *Biol Psychiatry* 80: 509–521.
- 711 36. Makris N, Rathi Y, Mouradian P, Bonmassar G, Papadimitriou G, Ing WI, *et al.* (2016): Variability
712 and anatomical specificity of the orbitofrontothalamic fibers of passage in the ventral
713 capsule/ventral striatum (VC/VS): precision care for patient-specific tractography-guided
714 targeting of deep brain stimulation (DBS) in obsessive compulsive disorder (OCD). *Brain*
715 *Imaging Behav* 10: 1054–1067.
- 716 37. Liebrand LC, Caan MWA, Schuurman PR, van den Munckhof P, Figuee M, Denys D, van Wingen
717 GA (2018): Individual white matter bundle trajectories are associated with deep brain stimulation

- 718 response in obsessive-compulsive disorder. *Brain Stimulat.*
719 <https://doi.org/10.1016/j.brs.2018.11.014>
- 720 38. Howell B, McIntyre CC (2016): Analyzing the tradeoff between electrical complexity and accuracy in
721 patient-specific computational models of deep brain stimulation. *J Neural Eng* 13: 036023.
- 722 39. Poldrack RA, Huckins G, Varoquaux G (2020): Establishment of best practices for evidence for
723 prediction: a review. *JAMA Psychiatry* 77: 534–540.
- 724 40. Grzenda A, Kraguljac NV, McDonald WM, Nemeroff CB, Torous J, Alpert JE, *et al.* (Accepted):
725 Evaluating the machine learning literature: a primer and user’s guide for psychiatrists. *Am J*
726 *Psychiatry*.
- 727 41. Lo A, Chernoff H, Zheng T, Lo S-H (2015): Why significant variables aren’t automatically good
728 predictors. *Proc Natl Acad Sci* 112: 13892–13897.
- 729 42. Widge AS, Bilge MT, Montana R, Chang W, Rodriguez CI, Deckersbach T, *et al.* (2019):
730 Electroencephalographic biomarkers for treatment response prediction in major depressive
731 illness: a meta-analysis. *Am J Psychiatry* 176: 44–56.
- 732 43. Woo C-W, Chang LJ, Lindquist MA, Wager TD (2017): Building better biomarkers: brain models in
733 translational neuroimaging. *Nat Neurosci* 20: 365–377.
- 734 44. Coenen VA, Schlaepfer TE, Varkuti B, Schuurman PR, Reinacher PC, Voges J, *et al.* (2019):
735 Surgical decision making for deep brain stimulation should not be based on aggregated
736 normative data mining. *Brain Stimul Basic Transl Clin Res Neuromodulation* 12: 1345–1348.
- 737 45. McLaughlin N, Dougherty DD, Eskandar EN, Ward HE, Foote KD, Malone Jr. DA, *et al.* (n.d.):
738 Double blind randomized controlled trial of deep brain stimulation for obsessive-compulsive
739 disorder: clinical trial design. *Contemp Clin Trials*.
- 740 46. Malcolm JG, Shenton ME, Rathi Y (2010): Filtered multitensor tractography [no. 9]. *IEEE Trans*
741 *Med Imaging* 29: 1664–1675.
- 742 47. Reddy CP, Rathi Y (2016): Joint Multi-Fiber NODDI Parameter Estimation and Tractography Using
743 the Unscented Information Filter. *Front Neurosci* 10. <https://doi.org/10.3389/fnins.2016.00166>

- 744 48. Gong S, Zhang F, Norton I, Essayed WI, Unadkat P, Rigolo L, *et al.* (2018): Free water modeling of
745 peritumoral edema using multi-fiber tractography: Application to tracking the arcuate fasciculus
746 for neurosurgical planning [no. 5]. *PLoS ONE* 13. <https://doi.org/10.1371/journal.pone.0197056>
- 747 49. Liao R, Ning L, Chen Z, Rigolo L, Gong S, Pasternak O, *et al.* (2017): Performance of unscented
748 Kalman filter tractography in edema: Analysis of the two-tensor model. *NeuroImage Clin* 15:
749 819–831.
- 750 50. Zhang F, Wu Y, Norton I, Rigolo L, Rathi Y, Makris N, O'Donnell LJ (2018): An anatomically curated
751 fiber clustering white matter atlas for consistent white matter tract parcellation across the
752 lifespan. *NeuroImage* 179: 429–447.
- 753 51. Chen Z, Tie Y, Olubiyi O, Rigolo L, Mehrtash A, Norton I, *et al.* (2015): Reconstruction of the
754 arcuate fasciculus for surgical planning in the setting of peritumoral edema using two-tensor
755 unscented Kalman filter tractography. *NeuroImage Clin* 7: 815–822.
- 756 52. Chaturvedi A, Luján JL, McIntyre CC (2013): Artificial neural network based characterization of the
757 volume of tissue activated during deep brain stimulation. *J Neural Eng* 10: 056023.
- 758 53. Butson CR, McIntyre CC (2006): Role of electrode design on the volume of tissue activated during
759 deep brain stimulation. *J Neural Eng* 3: 1–8.
- 760 54. O'Donnell LJ, Westin C-F (2007): Automatic tractography segmentation using a high-dimensional
761 white matter atlas [no. 11]. *IEEE Trans Med Imaging* 26: 1562–1575.
- 762 55. O'Donnell LJ, Wells WM, Golby AJ, Westin C-F (2012): Unbiased groupwise registration of white
763 matter tractography. In: Ayache N, Delingette H, Golland P, Mori K, editors. *Medical Image*
764 *Computing and Computer-Assisted Intervention – MICCAI 2012*, vol. 7512. Berlin, Heidelberg:
765 Springer Berlin Heidelberg, pp 123–130.
- 766 56. Couronné R, Probst P, Boulesteix A-L (2018): Random forest versus logistic regression: a large-
767 scale benchmark experiment. *BMC Bioinformatics* 19: 270.
- 768 57. Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP (2002): SMOTE: Synthetic Minority Over-
769 sampling Technique. *J Artif Intell Res* 16: 321–357.

- 770 58. Tyagi H, Apergis-Schoute AM, Akram H, Foltynie T, Limousin P, Drummond LM, *et al.* (2019): A
771 randomised trial directly comparing ventral capsule and anteromedial subthalamic nucleus
772 stimulation in obsessive compulsive disorder: clinical and imaging evidence for dissociable
773 effects. *Biol Psychiatry* 85: 726–734.
- 774 59. Smith GCS, Seaman SR, Wood AM, Royston P, White IR (2014): Correcting for optimistic
775 prediction in small data sets. *Am J Epidemiol* 180: 318–324.
- 776 60. Widge AS, Dougherty DD (2015): Managing patients with psychiatric disorders with deep brain
777 stimulation. In: Marks Jr. WJ, editor. *Deep Brain Stimulation Management*, 2nd ed. Cambridge :
778 New York: Cambridge University Press.
- 779 61. van Westen M, Rietveld E, Bergfeld IO, Koning P de, Vullink N, Ooms P, *et al.* (2021): Optimizing
780 deep brain stimulation parameters in obsessive–compulsive disorder. *Neuromodulation Technol*
781 *Neural Interface* 24: 307–315.
- 782 62. Mantione M, Nieman DH, Figeo M, Denys D (2014): Cognitive–behavioural therapy augments the
783 effects of deep brain stimulation in obsessive–compulsive disorder. *Psychol Med* 44: 3515–
784 3522.
- 785 63. van Westen M, Rietveld E, Denys D (2019): Effective deep brain stimulation for obsessive-
786 compulsive disorder requires clinical expertise. *Front Psychol* 10: 2294.
- 787 64. Burguière E, Monteiro P, Mallet L, Feng G, Graybiel AM (2015): Striatal circuits, habits, and
788 implications for obsessive–compulsive disorder. *Curr Opin Neurobiol* 30: 59–65.
- 789 65. Garnaat SL, Greenberg BD, Sibrava NJ, Goodman WK, Mancebo MC, Eisen JL, Rasmussen SA
790 (2014): Who qualifies for deep brain stimulation for OCD? Data from a naturalistic clinical
791 sample. *J Neuropsychiatry Clin Neurosci* 26: 81–86.
- 792 66. Duchin Y, Shamir RR, Patriat R, Kim J, Vitek JL, Sapiro G, Harel N (2018): Patient-specific
793 anatomical model for deep brain stimulation based on 7 Tesla MRI. *PLoS One* 13: e0201469.
- 794 67. Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, Munafò MR (2013): Power
795 failure: why small sample size undermines the reliability of neuroscience. *Nat Rev Neurosci* 14:
796 365–376.


- 797 68. Menchón JM, Real E, Alonso P, Aparicio MA, Segalas C, Plans G, *et al.* (2021): A prospective
798 international multi-center study on safety and efficacy of deep brain stimulation for resistant
799 obsessive-compulsive disorder [no. 4]. *Mol Psychiatry* 26: 1234–1247.
- 800 69. Greenberg B, Gabriels L, Malone D, Rezai A, Friehs G, Okun M, *et al.* (2010): Deep brain
801 stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder:
802 worldwide experience. *Mol Psychiatry* 15: 64–79.
- 803 70. Nuttin B, Cosyns P, Demeulemeester H, Gybels J, Meyerson B (1999): Electrical stimulation in
804 anterior limbs of internal capsules in patients with obsessive-compulsive disorder. *The Lancet*
805 354: 1526.
- 806 71. Basu I, Yousefi A, Crocker B, Zelmann R, Paulk AC, Peled N, *et al.* (Accepted in principle): Closed
807 loop enhancement and neural decoding of human cognitive control. *Nat Biomed Eng.*
808 <https://doi.org/10.1101/2020.04.24.059964>
- 809 72. Widge AS, Zorowitz S, Basu I, Paulk AC, Cash SS, Eskandar EN, *et al.* (2019): Deep brain
810 stimulation of the internal capsule enhances human cognitive control and prefrontal cortex
811 function. *Nat Commun* 10: 1536.
- 812 73. Gruner P, Pittenger C (2017): Cognitive inflexibility in Obsessive-Compulsive Disorder.
813 *Neuroscience* 345: 243–255.
- 814 74. Abramovitch A, Abramowitz JS, Mittelman A (2013): The neuropsychology of adult obsessive–
815 compulsive disorder: A meta-analysis. *Clin Psychol Rev* 33: 1163–1171.
- 816
817



818

819 **Figure 1:** Patient-specific tractographic mapping of OCD DBS response. (A), Tract tracing and
 820 activation modeling examples. Shown are left/right oblique and axial views from one non-responder and
 821 one responder, with cortico-thalamic and cortico-STN tracts indicated by different colors. DBS leads are
 822 shown in teal and VTAs in red. In this panel, we show only tracts intersecting the VTAs for clarity. (B),
 823 Tracing of tracts between STN and frontal cortex, in the same responder as (A). To ensure capture of
 824 the tract reported in (12), we broadly traced all streamlines originating in a seed around STN and
 825 extending anterior to the central sulcus. This includes fibers coursing dorsally to motor regions, and

826 tracts as in (12) connecting STN to ACC and medial PFC. Very few of these intersect the VTA in this
827 patient, despite the good clinical response (YBOCS drop of 61% from baseline). To emphasize that
828 point, this panel shows all fibers traced from the STN seed in this patient, regardless of VTA
829 intersection.




830

831 **Figure 2:** Non-zero regression coefficients across exhaustive leave-two-out cross-validation of
 832 regularized logistic regression to predict YBOCS response. All confidence intervals include 0, with left
 833 medial OFC (non-response) and left ACC (response) coming closest to significance. All reported results
 834 are for total fiber capture; percentage capture did not have non-zero coefficients in this analysis. Data
 835 are coded such that positive regression coefficients represent clinical improvement.

836

837



838

839

Figure 3: Non-zero regression coefficients across exhaustive leave-two-out cross-validation of

840

regularized logistic regression to predict MADRS response. All confidence intervals include 0, except

841

for the right cingulate cortex. All reported results are for total fiber capture; percentage capture did not

842

have non-zero coefficients in this analysis.

843

	R ²			Explained Variance		
	Median	CI Lower Bound	CI Upper Bound	Median	CI Lower Bound	CI Upper Bound
L1 Regression (Percentage)	-0.194	-1.743	1.355	0	0	0
L1 Regression (Total Fibers)	-0.196	-1.747	1.356	0	0	0
Random Forest (Percentage)	-0.792	-3.794	2.21	-0.023	-0.902	0.857
Random Forest (Total Fibers)	-1.389	-4.934	2.156	-0.222	-1.249	0.805

844

845 **Table 1:** Modeling outcomes for YBOCS improvement as a continuous variable. All confidence
846 intervals include 0. Negative coefficients of determination (R²) imply a model that performs worse than
847 chance.

848

849

850

	Balanced Accuracy			Recall			AUC		
	Median	CI Lower Bound	CI Upper Bound	Median	CI Lower Bound	CI Upper Bound	Median	CI Lower Bound	CI Upper Bound
L1 Logistic (Percentage)	0.5	0.5	0.5	0	0	0	0.5	0.5	0.5
L1 Logistic (Total Fibers)	0.5	0.093	0.907	0.571	-0.24	1.383	0.572	0.281	0.864
Random Forest (Percentage)	0.46	0.192	0.728	0	-0.582	0.582	0.58	0.368	0.793
Random Forest (Total Fibers)	0.421	0.193	0.65	0	-0.527	0.527	0.588	0.374	0.802

851

852 **Table 2:** Modeling outcomes for YBOCS improvement as a categorical response. All confidence
853 intervals include chance (0.5 for Balanced Accuracy and AUC, 0 for Recall of the minority class).

854

855

Tract	Training Set R			Test Set R ²		
	Median	CI Lower Bound	CI Upper Bound	Median	CI Lower Bound	CI Upper Bound
L dIPFC (Percentage)	-0.405	-0.607	-0.203	-0.139	-1.842	1.564
L vIPFC (Total Fibers)	-0.389	-0.591	-0.187	-0.268	-2.813	2.277
R vIPFC (Percentage)	-0.384	-0.504	-0.263	-0.162	-1.622	1.297
L STN (Percentage)	-0.373	-0.62	-0.125	-0.301	-3.189	2.587
L vIPFC (Percentage)	-0.366	-0.603	-0.129	-0.411	-27.119	26.297
R dmPFC (Percentage)	-0.359	-0.481	-0.237	-0.275	-2.182	1.633
R dIPFC (Percentage)	-0.356	-0.542	-0.17	-0.14	-1.706	1.426
All Regions (Percentage)	-0.347	-0.555	-0.138	-0.35	-1.598	0.897
L dIPFC (Total Fibers)	-0.332	-0.594	-0.07	-0.275	-2.149	1.6
R STN (Percentage)	-0.321	-0.525	-0.118	-0.315	-2.149	1.519
L dmPFC (Percentage)	-0.315	-0.567	-0.063	-0.434	-22.196	21.329
All Regions (Total Fibers)	-0.311	-0.553	-0.069	-0.421	-1.868	1.026
R dmPFC (Total Fibers)	-0.266	-0.471	-0.062	-0.35	-1.832	1.132
R vIPFC (Total Fibers)	-0.266	-0.461	-0.071	-0.182	-2.991	2.626
L ACC-PAC (Total Fibers)	0.268	0.067	0.469	-0.33	-1.959	1.298
R OFC-Lateral (Percentage)	0.319	0.07	0.567	-0.315	-1.771	1.141

856

857 **Table 3:** Correlations between individual fiber tracts and YBOCS response, in the style of (12), filtered
858 to tracts whose confidence interval excludes 0 on the training sets. No such tract has clinical predictive
859 power on held-out test sets (all R² values less than 0).

860

861

862

	Balanced Accuracy			Recall			AUC		
	Median	CI Lower Bound	CI Upper Bound	Median	CI Lower Bound	CI Upper Bound	Median	CI Lower Bound	CI Upper Bound
L1 Logistic (Percentage)	0.5	0.5	0.5	0	0	0	0.5	0.5	0.5
L1 Logistic (Total Fibers)	0.5	0.093	0.907	0.571	0	1	0.572	0.281	0.864
Random Forest (Percentage)	0.46	0.192	0.728	0	0	0.582	0.58	0.368	0.793
Random Forest (Total Fibers)	0.421	0.193	0.65	0	0	0.527	0.588	0.374	0.802

863

864 **Table 4:** Leave-two-out prediction outcomes for categorical depression response (MADRS). No model
865 exceeded chance accuracy on the test set (all confidence intervals include a balanced accuracy/AUC of
866 0.5 or recall of 0).

867

868 **Patient-Specific Connectomic Models Correlate With, But Do Not Predict, Outcomes in**
869 **Deep Brain Stimulation for Obsessive-Compulsive Disorder**

870 **Supplemental Methods**

871 *Study Population and Clinical Treatment*

872 In all cases, DBS implantation and programming followed the protocols described in (60). 2 patients
873 were implanted and followed at Butler Hospital/Brown University Medical School; the other 6 were
874 implanted and followed at Massachusetts General Hospital. All patients received Medtronic model 3387
875 DBS leads, with the most ventral contact targeted to the ventral striatal grey matter. All participants
876 gave informed consent after multiple meetings with the site study teams, which explicitly included
877 separate consent for neuroimaging.

878

879 One patient, reported in (76), declined rating visits with the study team after her first several months of
880 treatment, due to being substantially improved and not desiring further programming. She had a series
881 of telephone notes captured in the electronic medical record over the course of a year documenting that
882 she was doing well with no DBS setting changes from her last programming visit. We carried her
883 YBOCS and MADRS forward from the last available rating, despite suggestions in the clinical record
884 that she was doing better than these scores reflect.

885

886 *Imaging Details*

887 Pre-operative MRI data were acquired on a 3T Siemens TimTrio scanner. T1-weighted and T2-
888 weighted images were acquired with a 1.2 mm isotropic voxel size; diffusion MRI (dMRI) scans had a
889 spatial resolution of 2 mm (isotropic) with 10 non-diffusion weighted volumes and 60 diffusion weighted
890 volumes, with gradient directions spread uniformly on the sphere with a b-value of 700 s/mm². After

891 DBS implantation, a postoperative CT scan was acquired at a spatial resolution of 0.43 x 0.43 x 0.63
892 mm³.

893

894 All MRI data was processed using a published pipeline (43) available at <https://github.com/pnlbwh/>. We
895 applied axis alignment to the T1-weighted and T2-weighted images, and performed eddy current and
896 motion correction for the dMRI images. T1-weighted images were skull-stripped using the Brain
897 Extraction Toolkit (BET) (77,78). These masks were then manually checked and edited to ensure
898 accurate brain extraction. In a similar manner, the CT scans were also masked to only retain the brain.
899 The ANTS registration software (79) was then used to coregister the CT images to the T1-weighted
900 images as well as the dMRI scans. Further, Freesurfer (v6.1) was run on the T1-weighted images to
901 parcellate the brain (both cortex and subcortical structures) using the Desikan-Killiany atlas. Next, we
902 registered the Freesurfer segmentation to the diffusion weighted images using pipeline scripts. All
903 registrations (CT to T1-weighted, CT to dMRI, Freesurfer) were manually checked for accuracy.

904

905 During the tract tracing and annotation, fibers terminating in ACC vs. PAC could not be reliably
906 distinguished across all subjects. We thus treated these adjacent regions as a single terminus.

907

908 We defined the STN-PFC tracts as all streamlines connecting the STN with the following Freesurfer
909 segmented regions: caudal anterior cingulate, caudal middle frontal, lateral orbitofrontal, medial
910 orbitofrontal, parsopercularis, parsorbitalis, rostral anterior cingulate, rostral middle frontal, superior
911 frontal, and frontal pole. To ensure that we captured the relevant bundles, we dilated the STN by 1
912 voxel (~ 2mm) in all directions (from our hand drawn segmentations) to include more tracts that might
913 be close to the STN. These streamlines were analyzed identically to the cortico-thalamic tracts.

914

915 *Data Analysis - Hypomania*

916 We considered the possibility that pathway modeling might be more useful for minimizing off-target
917 effects than for determining response (23,80). The most common complication of VCVS DBS is a
918 hypomanic-impulsive syndrome that may affect up to 50% of patients (57,68). (We refer to this as
919 “hypomania” for conciseness, but acknowledge the substantial debate (61) over the naming and nature
920 of this complication.) We ascertained hypomania by chart review of visit notes and case report forms. 3
921 patients experienced at least one hypomanic episode, over 50 total visits. We again compared L1-
922 regularized logistic regression and random forest classification on this restricted dataset. It was not
923 possible to perform this analysis on the full dataset, because the rarity of the complication meant that
924 cross-validation strategies would produce training/test sets without sufficient examples. Further, it
925 would likely be possible to achieve above-chance classification by identifying which patient contributed
926 a given data point, which would be subtly reflected in the overall pattern of activation (i.e., there is a
927 strong potential for data leakage).

928

929 *Data Analysis - Model Evaluation*

930 We altered the cross-validation process for the hypomania model, because restricting the dataset to the
931 3 patients who experienced at least one hypomanic event made leave-2-out infeasible. We therefore
932 cross-validated at the level of individual visits. We split the dataset with 80% of the data points as
933 training and 20% as test set data, stratifying the split so that hypomanic events occurred in each
934 dataset. We repeated this splitting process 1,000 times to obtain confidence intervals, and again
935 performed all oversampling after the split.

936 *Data Analysis - Overall White Matter Integrity*

937 In a further exploration, we noted that some tracts had very few streamlines in non-responders. We
938 considered that white matter integrity might affect our results, such that patients could only respond if a
939 given tract were sufficiently intact. For every tract in the previous analyses, we defined its integrity as

940 the total number of streamlines traced, divided by the overall intracranial volume (to ensure that we did
941 not simply trace more fibers in larger brains). Following the total/percentage fiber analyses above, we
942 also created a predictor from the mean integrity across all tracked bundles. We could not correlate
943 integrity against response at the visit level, since tract integrity does not change with DBS settings.
944 Instead, we classified patients as overall responders if a plurality (40% or more) of their clinical visits
945 had YBOCS scores below the 35% response threshold; 3 of the 8 met this criterion. We did not
946 consider the first three months of the clinical course in determining this response, in order to emphasize
947 response from DBS as opposed to lesion effect. We did not SMOTE this analysis, as the dataset was
948 too small.

949

950 To test for a “threshold” level of integrity for DBS efficacy, we performed a Necessary Condition
951 Analysis (NCA, (81)), as implemented in R package “NCA” (82), using the free disposal hull (CE-FDH)
952 ceiling calculation. We separately tested the necessity of each tract and of overall (mean) integrity. We
953 assessed significance of the resulting NCA effect sizes by 1000-fold permutation (shuffling
954 responder/non-responder labels), with Benjamini-Hochberg false discovery rate correction.

955

956

957 **Supplemental Results**

958 *Hypomania*

959 3 patients (37.5%) experienced hypomania (6 total episodes) in this dataset. This is somewhat below
 960 the rate we reported from a different VCVS dataset (57), but consistent with the largest published
 961 cohort of this target in OCD (68).


962
 963 No model was able to predict hypomania with better than chance performance (Table S5). Further, all
 964 fitted models had 0 median recall, i.e. predictive power was generally achieved by always predicting the
 965 majority (non-hypomanic) outcome. The percentage-capture regression model assigned all coefficients
 966 to 0, whereas the total-fiber model had some nonzero coefficients (Figure S4). Specifically, the left-
 967 sided PFC-STN connection was protective against hypomania. The left DLFPC-thalamus fibers had a
 968 similar but non-significant effect. Activation of right lateral OFC and STN fibers, on the other hand,
 969 predisposed towards hypomania, consistent with a prior analysis that found an association between
 970 right-sided monopolar stimulation and hypomania (57). The random forest model had no importance
 971 scores that systematically differed from zero.

972
 973

	Balanced Accuracy			Recall			AUC		
	Median	CI Lower Bound	CI Upper Bound	Median	CI Lower Bound	CI Upper Bound	Median	CI Lower Bound	CI Upper Bound
L1 Logistic (Percentage)	0.5	0.5	0.5	0	0	0	0.5	0.5	0.5
L1 Logistic (Total Fibers)	0.4	0	0.84	0	0	0.899	0.7	0.486	0.914
Random Forest (Percentage)	0.5	0.043	0.957	0	0	0.912	0.55	0.152	0.948
Random Forest (Total Fibers)	0.5	0.003	0.997	0	0	0.988	0.55	0.109	0.991

974

975 **Table S5:** Prediction outcomes for hypomania, on a test set composed of 20% of visits from the 3
 976 patients who had hypomanic episodes. No model consistently achieves recall > 0 or better than chance
 977 accuracy/AUC.



979

980

Figure S4: Non-zero regression coefficients for regularized logistic regression to predict hypomania.

981

The only tract whose confidence interval excludes 0 connected left PFC to STN, and was protective

982

against hypomania. All reported results are for total fiber capture; percentage capture did not have non-

983

zero coefficients in this analysis. Here, positive coefficients signify greater risk of hypomania.

984

985

White Matter Integrity

986

There was substantial variability in white matter integrity among individual patients and tracts (Table

987

S2). Overall (mean) white matter integrity had a moderate effect size in the NCA (0.62). Consistent with

988

the regression analyses, the left and right cingulo-thalamic tracts had the highest effect size of any

989

individual tract. None of these effects reached significance even at the uncorrected level (Table S3).

990

Subj	L ACC-PAC	L dIPFC	L dmPFC	L OFC-Lateral	L OFC-Medial	L vIPFC	L STN	R ACC-PAC	R dIPFC	R dmPFC	R OFC-Lateral	R OFC-Medial	R vIPFC	R STN	Mean Integrity	Responder
A	0.064	0.280	0.306	0.017	0.029	0.414	0.220	0.155	0.331	1.083	0.016	0.010	0.691	0.115	0.278	N
B	0.187	0.506	1.076	0.012	0.055	0.279	0.025	0.160	0.319	1.718	0.013	0.033	0.713	0.025	0.392	Y
C	0.003	0.063	0.117	0.000	0.002	0.075	0.005	0.002	0.167	0.239	0.000	0.000	0.041	0.005	0.055	N
D	0.280	0.364	0.669	0.081	0.080	0.473	0.093	0.210	0.342	0.588	0.057	0.023	0.169	0.102	0.264	Y
E	0.148	0.470	0.834	0.043	0.089	0.057	0.105	0.296	1.079	0.993	0.008	0.011	0.418	0.104	0.350	N
F	0.194	0.398	0.871	0.038	0.092	0.226	0.054	0.263	0.302	1.206	0.051	0.126	0.688	0.074	0.347	N
G	0.311	0.655	1.327	0.018	0.042	0.145	0.567	0.156	0.413	0.589	0.016	0.056	0.149	0.166	0.342	Y
H	0.098	0.309	0.806	0.100	0.308	0.084	0.103	0.128	0.257	1.283	0.043	0.116	0.198	0.176	0.295	N

991

992 **Table S6:** White matter integrity. Each cell represents the number of traced streamlines within a given tract, divided by each subject's
993 intracranial volume. Responder/nonresponder status is determined by the fraction of clinical visits where the YBOCS had improved 35% or
994 more from baseline.

995

996

997

998
999

Name	Effect Size	p	p(FDR)
Mean Integrity	0.620	0.635	0.635
L ACC-PAC	0.595	0.077	0.475
R ACC-PAC	0.526	0.190	0.475
L dIPFC	0.509	0.190	0.475
L dmPFC	0.456	0.373	0.622
R dmPFC	0.236	0.635	0.635
R OFC-Lateral	0.225	0.335	0.622
L vIPFC	0.211	0.170	0.475
R OFC-Medial	0.182	0.178	0.475
R dIPFC	0.167	0.187	0.475
R vIPFC	0.160	0.635	0.635
L OFC-Medial	0.130	0.373	0.622
L OFC-Lateral	0.123	0.635	0.635
R STN	0.113	0.635	0.635
L STN	0.036	0.635	0.635

000

001 **Table S3:** Necessary Condition Analysis for white matter integrity predicting YBOCS response, with p-
002 values from 1000-fold bootstrap resampling, both raw and False Discovery Rate corrected. No variable
003 reaches corrected or uncorrected significance.

004